A DTC telehealth brand selling GLP-1 weight loss, hormone therapy, and hair treatment should run one ad account and one measurement dataset, then separate everything downstream of that: one campaign per product line, one conversion event per line, one landing path per line, and one creative pool per line. Shared accounts keep signal and billing consolidated. Separated campaigns keep a policy rejection on one line from throttling the other two.
ClinicAds has already published what a telehealth patient costs by vertical and how LTV-to-CAC and payback period should be read. This post answers a different question with a different dataset: it is about account architecture rather than benchmarks, and it prices structural decisions rather than patients. A brand that already knows GLP-1 costs more to acquire than hair uses this post to decide where the two lines share plumbing, where they must not, and what happens to the account when one of them gets flagged.
- A multi-line DTC telehealth brand runs one ad account and one measurement dataset, then separates at the campaign layer: one campaign per product line, its own conversion event, its own landing path, and its own creative pool.
- GLP-1 weight loss is the policy risk in the account. Isolating GLP-1 creative into its own campaign and its own landing path keeps a rejection from stalling hormone and hair delivery alongside it.
- Budget follows payback, not equal thirds. A $30,000 monthly budget commonly sits near 45 to 55 percent GLP-1, 25 to 35 percent hormone, and 15 to 25 percent hair.
- Every line optimizes toward a paying patient, not a lead. Lines that cannot produce enough weekly conversions to hold an optimization signal optimize one step earlier, at intake started.
How should a telehealth brand structure a multi-line ad account?
A multi-line DTC telehealth account shares its top layer and separates its middle layer. One business manager, one ad account per platform, and one server-side measurement dataset keep conversion signal, domain verification, and billing consolidated. Below that, each product line gets its own campaign, conversion event, landing path, and creative pool, so performance is readable per line and a problem on one line stays on that line.
The reason to share the top layer is signal. Platform learning improves with volume inside a single verified dataset, and domain verification, business verification, and the healthcare-related restrictions that follow them are administered at the account and domain level rather than per campaign. Splitting a $30,000 monthly budget across three ad accounts triples the administrative surface without improving delivery on any of the three.
The reason to separate the middle layer is containment and readability. GLP-1 weight loss, hormone therapy, and hair treatment have different policy exposure, different CAC ranges, and different payback periods, and a campaign that mixes them produces a blended cost per acquisition that describes none of the three. ClinicAds structures these accounts so that every number a brand looks at belongs to exactly one product line.
- Layer 1, shared: business manager, ad account, pixel and server-side dataset, verified domain, billing.
- Layer 2, separated: one campaign per product line, named by line so reporting filters cleanly.
- Layer 3, separated: one primary conversion event per line, defined at the paying-patient step.
- Layer 4, separated: one landing path per line, on its own URL folder under the verified domain.
- Layer 5, separated: one creative pool per line, with no shared assets across lines.
Should GLP-1, hormone, and hair share one ad account?
GLP-1, hormone, and hair should share one ad account in almost every case, and should never share a campaign. Meta and Google administer most enforcement at the asset and campaign level, so a rejected GLP-1 ad inside a mixed campaign disrupts delivery for the hormone and hair ads sitting in the same ad sets. Separating campaigns keeps a rejection local. The exception is an account that has already taken repeated account-level warnings on GLP-1 creative.
GLP-1 weight loss is the line that creates policy exposure for the rest of the account. Meta restricts branded pharmaceutical weight-loss terminology and most weight-loss before-and-after imagery, and Google requires certification for pharmacy-related advertising. Hormone and hair advertising carry real requirements of their own, but neither generates rejections at the rate GLP-1 does. A structure that leaves GLP-1 creative loose in a shared campaign lets the most restricted line set the delivery ceiling for the least restricted one.
When a brand has already collected two or more account-level warnings on GLP-1, ClinicAds moves GLP-1 to a separate ad account under the same business manager, on a separate verified subdomain, while hormone and hair stay together. That preserves the rest of the account if GLP-1 enforcement escalates. The cost of that move is a split dataset and slower learning on the GLP-1 side, which is why it is a response to a warning history rather than a default.
How should budget be split across three telehealth lines?
Budget across GLP-1, hormone, and hair should follow payback speed and LTV rather than equal thirds. At a $30,000 monthly budget, a common allocation is 45 to 55 percent to GLP-1, 25 to 35 percent to hormone, and 15 to 25 percent to hair. GLP-1 takes the largest share because it carries the highest CAC and the narrowest compliant targeting, so it needs volume to hold a stable optimization signal. These are agency averages, not guarantees.
The allocation is not a statement about which line is most valuable. Hormone and TRT patients carry the highest lifetime value of the three, commonly $1,200 to $2,000, but hormone campaigns reach an efficient cost per paying patient at lower spend than GLP-1 does, so pushing more budget into hormone past that point raises CAC without adding proportional volume. Hair sits at the bottom of the CAC range, roughly $90 to $150 per paying patient, and its role in the account is to produce steady, cheap volume that keeps blended economics healthy while the other two lines mature.
| Line | Share of budget | Monthly spend | Structural reason for the share |
|---|---|---|---|
| GLP-1 weight loss | 45 to 55 percent | $13,500 to $16,500 | Highest CAC and narrowest compliant targeting, so the line needs volume to hold optimization |
| Hormone / TRT | 25 to 35 percent | $7,500 to $10,500 | Highest LTV of the three, but reaches efficient CAC at lower spend than GLP-1 |
| Hair | 15 to 25 percent | $4,500 to $7,500 | Cheapest acquisition and predictable refills, so the line stabilizes blended account economics |
What conversion event should each line optimize for?
Every line in a DTC telehealth account should optimize toward a paying patient, defined as a completed intake plus a first paid order, rather than toward a lead or a free quiz completion. Optimizing on quiz completions trains the platform to find people who finish quizzes, and telehealth quiz completion converts to a paid plan inconsistently enough that the two audiences are not the same. The exception is a line with too little weekly volume to hold that signal.
Platform optimization needs roughly 50 conversions per week per ad set to leave the learning phase and hold a stable cost. A hair line spending $5,000 a month at a $120 CAC produces about 42 paying patients a month, which is roughly 10 a week and well under the threshold. That line optimizes one step earlier, at intake started, and the account then watches the intake-to-paid rate as a separate number rather than trusting the platform to protect it.
The sequencing matters more than the specific event. ClinicAds sets each line to optimize at the deepest event that clears the volume threshold, then moves the event deeper as spend grows. A GLP-1 line at $15,000 a month and a $200 CAC produces about 75 paying patients a month, which supports optimizing directly on the paid event. All figures are agency averages, not guarantees.
- Above roughly 50 paying patients per week on a line: optimize on first paid order.
- Between roughly 15 and 50 per week: optimize on intake started, report on paid.
- Below roughly 15 per week: optimize on intake started and consolidate ad sets rather than adding more.
Why does each line need its own landing path?
Each product line needs its own landing path because ad review reads the destination, not only the ad. A GLP-1 ad pointing at a homepage that also markets hormone therapy and hair treatment is reviewed against the content of that whole page, which imports the compliance requirements of every line into every review. Separate paths under the verified domain keep each review scoped to one line and one claim set.
Separate landing paths also produce clean measurement. When GLP-1, hormone, and hair traffic all lands on one page and branches from there, the branch point becomes an uncontrolled variable: a change to the page navigation moves conversion rate on all three lines at once and the account cannot tell which line actually changed. A brand running three paths on one verified domain, such as one folder per line, gets three independent conversion rates it can act on.
The path should carry the intake for that line as well as the education for it. A patient who clicked a hormone ad and has to select a category on arrival has been asked to re-declare something the click already established, and each additional step before intake costs conversion rate. ClinicAds keeps the line's ad, landing path, and intake form on one continuous route with no category selection in the middle.
How should creative be separated across lines?
Creative should be built per line and never shared across lines, because the claims a telehealth brand can make differ by condition and the review outcome differs with them. A hair testimonial that passes review is not evidence a similarly structured GLP-1 testimonial will pass, because weight-loss results imagery sits under restrictions hair imagery does not. Reusing an approved asset across lines transfers no approval and risks the account's standing.
Creative volume should also differ by line. GLP-1 needs the deepest rotation because more of its concepts get rejected and because condition-education creative fatigues faster than product creative. ClinicAds typically runs 8 to 12 active GLP-1 concepts, 5 to 8 hormone concepts, and 4 to 6 hair concepts on a $30,000 monthly account, and treats a rejection rate above roughly 20 percent on a line as a signal that the line's creative brief needs rewriting rather than that more variations are needed.
Each line should keep two or three approved concepts in reserve that are deliberately conservative, meaning condition education with no results imagery and no branded drug terminology. A brand that loses its top GLP-1 concept to a policy change on a Thursday needs something already approved to carry spend through the weekend, and building that replacement after the rejection costs several days of delivery.
How do you budget when payback periods differ by line?
Lines with different payback periods should scale at different speeds. A line that returns its acquisition cost in 8 weeks can absorb weekly budget increases safely because the cash comes back before the next several increases compound. A line that takes 13 weeks to pay back ties up more cash per dollar of growth, so it should be held closer to flat unless the brand has decided to fund that gap deliberately. Telehealth payback across these three lines commonly runs 6 to 13 weeks.
The practical consequence is that hair often funds the growth of the other two lines, even though hair carries the lowest LTV of the three. Hair returns cash fastest, so a brand scaling hair and holding GLP-1 flat through a policy review cycle is not retreating from GLP-1. It is choosing the line whose cash comes back soonest while the restricted line is unstable. All payback figures here are agency averages, not guarantees.
| Line | Typical payback | How to scale it | Rebalance trigger |
|---|---|---|---|
| Hair | 6 to 10 weeks | Weekly budget steps of 15 to 20 percent | CAC above $150 for two consecutive weeks |
| Hormone / TRT | 7 to 11 weeks | Weekly budget steps of 10 to 15 percent | Intake-to-paid rate falls more than 10 points below its trailing quarter |
| GLP-1 weight loss | 9 to 13 weeks | Hold flat through any active policy review | Two rejections inside 14 days on the same ad account |
What should you measure per line, and when do you rebalance?
A multi-line telehealth account should report four numbers per line every week: cost per paying patient, intake-to-paid rate, week-one retention, and creative rejection rate. Blended account CAC should be reported but never acted on, because a blended number moves when the mix moves and hides which line changed. Rebalancing happens monthly on the numbers, not weekly on the noise.
The rebalance decision is a comparison of marginal return, not of absolute CAC. GLP-1 will always look worse than hair on cost per paying patient and that is not a reason to move budget. The question is whether the next $1,000 into a line returns more than the last $1,000 did, which shows up as cost per paying patient rising on a line while volume stays flat.
- 1. Pull cost per paying patient per line for the trailing 30 days, excluding the current week.
- 2. Compare each line to its own trailing quarter rather than to the other two lines.
- 3. Move budget only from a line whose CAC rose more than 15 percent while volume stayed flat.
- 4. Cap any single monthly move at 20 percent of a line's budget so optimization does not restart.
- 5. Re-verify that the server-side dataset is still reporting all three lines before reading any of it.
Can one campaign cover GLP-1, hormone, and hair if the budget is small?
No. A shared campaign is the structure that lets a GLP-1 rejection disrupt hormone and hair delivery, and that risk does not shrink with budget. A brand under roughly $10,000 a month should run three campaigns with one ad set each rather than one campaign with three ad sets, then consolidate ad sets inside a line before it consolidates lines.
Does separating campaigns hurt the platform's learning?
Separating campaigns costs less learning than most brands expect, because the shared pixel and server-side dataset still collect every conversion across all three lines. What separates is budget and optimization, not signal. The real learning risk is an underfunded line running four ad sets, which is why ClinicAds consolidates ad sets within a line rather than merging lines.
Should each product line have its own domain?
Usually not. One verified domain with a separate folder per line keeps domain verification, server-side tracking, and brand equity consolidated while still giving each line its own review surface and its own conversion rate. A separate domain is warranted only when a brand has moved GLP-1 into its own ad account after repeated account-level warnings.
What does this structure cost to run compared with a single campaign?
The structure adds build time rather than media cost, typically one to two weeks of setup covering campaign build, three landing paths, event definitions, and server-side configuration. Media budget is unchanged. A brand managing $10,000 to $50,000 a month in telehealth spend recovers that setup time in readable per-line economics within the first reporting month.
How long before a restructured account shows a difference?
Per-line cost per paying patient becomes readable in two to three weeks, once each line has cleared its optimization reset. Payback effects take a full cycle, so 9 to 13 weeks on GLP-1 and 6 to 10 on hair. ClinicAds does not rebalance budget inside the first 30 days after a restructure because the early numbers are still learning-phase artifacts. These are agency averages, not guarantees.